New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2012
16:57 EDTFLEX, ALIMAlimera Sciences, Flextronics enter manufacturing services agreement
Alimera Sciences (ALIM) entered into a Manufacturing Services Agreement with Flextronics Medical Sales and Marketing. Under the Agreement, Flextronics (FLEX) will manufacture Alimera’s proprietary inserter system for use with ILUVIEN, Alimera’s sustained release intravitreal implant for the treatment of chronic diabetic macular edema. Under the Agreement, Alimera will pay certain per Product unit prices based on regularly scheduled shipments of a minimum number of Product units.
News For ALIM;FLEX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:40 EDTFLEXUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 19 at 10:45 am; not all company presentations may be webcasted.Webcast Link
November 17, 2014
11:46 EDTALIMAlimera Sciences' ILUVIEN receives marketing approval in Ireland
Subscribe for More Information
10:02 EDTALIMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:55 EDTALIMAlimera Sciences initiated with a Buy at Summer Street
Target $12.
November 13, 2014
08:37 EDTFLEXUnilife and Flextronics enter into global strategic alliance
Unilife (UNIS) signed a Global Strategic Alliance Agreement with Flextronics (FLEX) to further expand the production capacity and scale-up capability of Unilife's product portfolio. In addition to Unilife fully utilizing its own FDA-registered manufacturing facilities in York, Pennsylvania, Flextronics will serve as a secondary source of supply to Unilife and its pharmaceutical customers.
November 12, 2014
07:43 EDTALIMAlimera Sciences' Iluvien receives marketing authorization in Belgium
Alimera Sciences,announced that the Belgian Federal Agency for Medicines and Health Products has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Approval in Belgium marks the fourth European approval through the Repeat-Use application procedure and the 12th approval worldwide, including the recent U.S. approval for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. To date, ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany. ILUVIEN is pending approval in an additional six European Union countries included in the Repeat-Use application procedure. These countries are the Czech Republic, Finland, Ireland, Luxembourg, the Netherlands and Poland.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use